Therefore, SGLT2 overexpression inhibition is a potential new target for highly prevalent hyperinsulinemia related conditions, namely some dysglycemic phenotypes and obesity. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.